Hematopoietic Stem Cell TransplantationHematopoietic Stem CellsTransplantation, HomologousStem Cell TransplantationTransplantation, AutologousTransplantation ConditioningGraft vs Host DiseasePeripheral Blood Stem Cell TransplantationStem CellsHematologic NeoplasmsBone Marrow TransplantationTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsTransplantation ChimeraTissue DonorsCord Blood Stem Cell TransplantationHematopoiesisGraft SurvivalMyeloablative AgonistsHematopoietic Stem Cell MobilizationHistocompatibility TestingWhole-Body IrradiationBusulfanHistocompatibilityAntigens, CD34Combined Modality TherapyLeukemiaRecurrenceGraft vs Leukemia EffectChimerismRetrospective StudiesLiver TransplantationDisease-Free SurvivalCell DifferentiationSurvival RateHematologic DiseasesBone Marrow CellsCyclophosphamideSurvival AnalysisMesenchymal Stem Cell TransplantationImmunosuppressive AgentsMultiple MyelomaRemission InductionTime FactorsHepatic Veno-Occlusive DiseaseLeukemia, Myeloid, AcuteHLA AntigensVidarabineSiblingsCell LineageMyelodysplastic SyndromesUnrelated DonorsCell TransplantationMelphalanStem Cell NicheEmbryonic Stem CellsFlow CytometryGraft vs Tumor EffectAdult Stem CellsTransplantation ImmunologyBone MarrowSalvage TherapyMice, Inbred C57BLSevere Combined ImmunodeficiencyKidney TransplantationLymphocyte TransfusionGranulocyte Colony-Stimulating FactorPrecursor Cell Lymphoblastic Leukemia-LymphomaFollow-Up StudiesAntineoplastic AgentsFetal BloodColony-Forming Units AssayTransplantation, IsogeneicPrognosisCytomegalovirus InfectionsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntilymphocyte SerumChemotherapy, AdjuvantAnemia, AplasticLymphoma, Non-HodgkinDonor SelectionAcute DiseaseT-LymphocytesAllograftsLymphocyte DepletionCells, CulturedCell SeparationGraft RejectionMesenchymal Stromal CellsCell ProliferationCytarabineEtoposideOpportunistic InfectionsImmunocompromised HostPluripotent Stem CellsStem Cell FactorMultipotent Stem CellsImmunosuppressionLymphoproliferative DisordersLeukemia, Myeloid